Gosuranemab  (Synonyms: BMS-986168; IPN007; BIIB092)

Gosuranemab (BMS-986168; IPN007) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the researches of alzheimer’s disease (AD) and progressive supranuclear palsy (PSP)^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Tau

Gosuranemab preincubated with AD-tau significantly inhibits tau aggregation in murine primary cortical neurons^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gosuranemab inhibits tau aggregation, reduces microglial cell activation and improves cognitive function deficits in the CSF of transgenic mice^[2][3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4137  [NCBI]

P10636

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.94 kDa

1788032-39-2

Liquid

Colorless to light yellow

[Gosuranemab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Fetal-tau/0N3R Protein, Human (His, solution, HY-P73618) can bind Gosuranemab. The EC₅₀ for this effect is 3.367 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ SHSY5Y cells with Gosuranemab (HY-P99648, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.

• [1]. Song C, et al. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.  [Content Brief]

  [2]. Imbimbo BP, et al. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 2022 May;18(5):1008-1037.  [Content Brief]

  [3]. Qureshi IA, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (N Y). 2018 Dec 17;4:746-755.  [Content Brief]